259 related articles for article (PubMed ID: 28466543)
21. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
22. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Li X; Song W; Shao C; Shi Y; Han W
Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
[TBL] [Abstract][Full Text] [Related]
23. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Gettinger S; Choi J; Hastings K; Truini A; Datar I; Sowell R; Wurtz A; Dong W; Cai G; Melnick MA; Du VY; Schlessinger J; Goldberg SB; Chiang A; Sanmamed MF; Melero I; Agorreta J; Montuenga LM; Lifton R; Ferrone S; Kavathas P; Rimm DL; Kaech SM; Schalper K; Herbst RS; Politi K
Cancer Discov; 2017 Dec; 7(12):1420-1435. PubMed ID: 29025772
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoints and cancer in the immunogenomics era.
Park R; Winnicki M; Liu E; Chu WM
Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
[TBL] [Abstract][Full Text] [Related]
25. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
26. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
27. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
Hayashi T; Kobayashi Y; Kohsaka S; Sano K
Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
[TBL] [Abstract][Full Text] [Related]
28. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
30. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
34. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
Dolan DE; Gupta S
Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
[TBL] [Abstract][Full Text] [Related]
35. Interferon Signaling Is Frequently Downregulated in Melanoma.
Alavi S; Stewart AJ; Kefford RF; Lim SY; Shklovskaya E; Rizos H
Front Immunol; 2018; 9():1414. PubMed ID: 29977240
[TBL] [Abstract][Full Text] [Related]
36. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
Ren Y; Zhang Y; Liu RZ; Fenstermacher DA; Wright KL; Teer JK; Wu J
Sci Rep; 2013 Oct; 3():3042. PubMed ID: 24154688
[TBL] [Abstract][Full Text] [Related]
37. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
39. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
Braun DA; Burke KP; Van Allen EM
Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
